Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558843 | 0.84 | LMNA (0.42) | LMNATDP1NR1H2NR1H3SRD5A1 | |
| SCHEMBL17002611 | 0.78 | KDM4E (0.48) | TDP1SRD5A1MAPK1 | |
| Acetic Acid SCHEMBL27709877 | 0.78 | KDM1A (0.42) | LMNATDP1NR1H2NR1H3SRD5A1 | |
| SCHEMBL24700489 | 0.77 | CYP2C19 (0.48) | NR1H2NR1H3 | |
| SCHEMBL28223122 | 0.77 | SRD5A1 (0.46) | LMNATDP1SRD5A1MAPK1SMN1; SMN2 | |
| SCHEMBL10718250 | 0.74 | LMNA (0.35) | LMNATDP1NR1H2NR1H3HDAC9 | |
| SCHEMBL8409794 | 0.74 | HDAC9 (0.49) | NR1H2NR1H3HDAC9MAPK1SMN1; SMN2 | |
| SCHEMBL8406842 | 0.73 | HDAC9 (0.39) | LMNATDP1NR1H2NR1H3HDAC9 | |
| SCHEMBL7573698 | 0.73 | SRD5A1 (0.43) | SRD5A1MAPK1SMN1; SMN2 | |
| SCHEMBL30695276 | 0.73 | SRD5A1 (0.43) | SRD5A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | LMNA 4351/4885TDP1 3043/4885NR1H2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.